Invitrogen, a provider of life science technologies, has entered
into new licensing agreements to supply its Gateway Technology and
clones to worldwide genomic research centres. This will allow
scientists and laboratories to share...
A new report into pharmaceutical R&D has identified an emerging
trend favouring outsourcing of discovery research, clinical trials
and formulation manufacturing, providing pressure relief from
consistent, high-growth financial...
Antibody technology company MorphoSys has formed a marketing
collaboration with Genefrontier, with a view to accessing the
Japanese life science market. This agreement will aim to establish
MorphoSys' HuCAL technology in the...
Medarex has announced a global collaboration agreement with Pfizer
that will provide for the discovery and development of up to 50
antibody products over ten years including the creation of fully
human antibody products in a variety...
Accelrys has signed a $21.5 million (€17.6 million) agreement to
merge SciTegic with one of its subsidiaries in a deal that will add
additional data analysis and mining software design capabilities to
Accelrys' extensive portfolio...
US life science company Serologicals has entered into a €167.6
million merger with cell signallin specialist Upstate, creating a
significant presence in the preclinical drug screening and target
validation market, the fastest growing...
US software systems provider, Genedata, has released the latest
version of Screener, a data analysis and management software system
for high throughput screening and compound profiling of
pharmacological properties and chemical structure,...
Germany's LION bioscience has made a foray into the market for
cheminformatics software with a new package designed to help
pharmaceutical companies identify, select and priortise compounds,
based on data emerging from the medicinal...
Technology holding company Coastal Holdings, has purchased a
significant equity interest in another biotechnology business,
adding to its portfolio of acquisitions and investments in the
biotechnology and nanotechnology fields.
A unique approach to microdosing, providing drug data ahead of
schedule and with improved accuracy, could herald a new era in drug
development in which human ADME data is involved in candidate
selection or deselection.